Feed / JNJ

Johnson & Johnson

JNJ

Healthcare · 273.23 +0.1% today

Partial group confirmationMarket checked 25 Aug, 15:55 GMT-4

Jodie situation report

Johnson & Johnson's move is being confirmed by its market group.

JNJ accounts for 2.1% of the group's measured movement across 7.1 effective names. raw member direction is mixed; 0 of 11 SPY-adjusted paths align to the mixed. Capital-flow agreement is 28%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveIndependent mover#10 of 11 by movement share
Group movement share2.1%Absolute path energy—not portfolio weight
Relative path+0.14%mixed
Effective breadth7.1 / 11broad
Relative alignment0/11mixed path · 0 counter-moving
Capital-flow agreement28%not yet clean
SEQUENCE READ

PBH, RPRX, BMY moved materially before JNJ. JNJ crossed its material path threshold at 11:20 ET, 50 minutes after the first measured mover. VCEL followed.

EVIDENCE COVERAGE

6 of 11 members in Biopharmaceuticals and Care are active. 0 of 4 disclosed connections are confirming.

What would change this read
  • At least 8 of 11 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as INVA begins moving with the group.

Invalidation: The live read weakens if participation falls to 3 of 11 members or fewer.

Watch this read

Who this business touches

The relationships behind JNJ

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

ABBVAbbVie Inc.partnerFeb 11, 2026 ▾

“The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and…”

KVUEKenvue Inc.partnerFeb 11, 2026 ▾

“Additionally, Johnson & Johnson and Kenvue entered into TMAs pursuant to which Johnson & Johnson will manufacture and supply to Kenvue certain products and, similarly, Kenvue will manufacture and supply to Johnson & Johnson certain products.”

LEGNLegend Biotech CorporationpartnerFeb 11, 2026 ▾

“The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and…”

Filing peers

MDTSUPNLLY

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

JNJ is currently a Early Follower in the organic co-movement group Biopharmaceuticals and Care. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.